UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/582,316	02/20/2007	Xin Lu	31265/5868A	1608	
	4743 7590 05/23/2008 MARSHALL, GERSTEIN & BORUN LLP			EXAMINER	
233 S. WACKER DRIVE, SUITE 6300			DAVIS, MINH TAM B		
SEARS TOWER CHICAGO, IL 60606			ART UNIT	PAPER NUMBER	
,			1642		
			MAIL DATE	DELIVERY MODE	
			05/23/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/582,316	LU ET AL.
Office Action Summary	Examiner	Art Unit
	MINH-TAM DAVIS	1642
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  (36(a). In no event, however, may a reply be till  will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. mely filed I the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on <u>08 J</u> This action is <b>FINAL</b> . 2b) ☐ This action is <b>FINAL</b> .      Since this application is in condition for alloware closed in accordance with the practice under <u>B</u>	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1,5,11-20 and 22-34 is/are pending in 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1, 5, 11-20, 22-34 are subject to restrict the subject to restrict the content of	wn from consideration.	ıt.
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6) Other:	ate

## **DETAILED ACTION**

Claims 1, 5, 11-20, 22-34 are pending and are subjected to the following restriction requirement.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1, 5, 18, 29, 32-33, drawn to the polypeptide SEQ ID NO:1 and a method for screening a peptide or polypeptide modulator of the binding of SEQ ID NO:1 to p53 polypeptide.

Group 2, claim(s) 11-12, 19-20, 22-28, drawn to drawn to the nucleic acid SEQ ID NO:2.

Group 3, claims 13-17, drawn to an antibody that binds to SEQ ID NO:1.

Group 4, claim 30, drawn to a method for screening an agent that modulates the binding of the polypeptide SEQ ID NO:3 with Bcl-2 polypeptide.

Group 5, claim 31, drawn to a method for screening an agent that modulates the ubiquitination of a polypeptide, using the polypeptide SEQ ID NO:1.

Group 6, claims 29, 31, drawn to a method for screening a nucleic acid modulator of the binding of SEQ ID NO:1 to p53 polypeptide.

The inventions are distinct, each from the other because of the following reasons:

Application/Control Number: 10/582,316 Page 3

Art Unit: 1643

A national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. When claims to different categories are present in the application, the claims will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and a process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said product, and an apparatus or means specifically designed for carrying out the said product, and an apparatus or means specifically designed for carrying out the said process. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, see PCT article 17(3) (a) and 1.476 (c), 37 C.F.R. 1.475(b) and (d). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d).)

Group I, claims 1, 5, 18, 29, 32-33, forms a single general inventive concept.

Groups 2-3 do not share the same technical feature of group I, because the composition of groups 2-3 do not share a common structure with the polypeptide SEQ ID NO:1 of group I.

Groups 5-6 are additional use of the polypeptide SEQ ID NO:1

Group 4 does not share the same technical feature of group I, because the methods of group 4 do not use the polypeptide SEQ ID NO:1 of group I.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, LARRY HELMS can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/582,316 Page 5

Art Unit: 1643

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH-TAM DAVIS May 11, 2006

/Larry R. Helms/ Supervisory Patent Examiner, Art Unit 1643